Active and inactive gastroesophageal reflux diseases related to Helicobacter pylori therapy

Helicobacter

Volumn 8, Issue 4, 2003, Pages 279-293

  Nakajima, Shigemi ^a   Hattori, Takanori ^b  

^a Social Insurance Shiga Hospital   (Japan)

^b NONE

Author keywords

Barrett's esophagus; Chronic atrophic gastritis; Esophageal adenocarcinoma; Gastric cancer; Gastroesophageal reflux disease; Reflux esophagitis

Indexed keywords

ANTACID AGENT; ANTIBIOTIC AGENT;

ADENOCARCINOMA; CANCER INCIDENCE; CANCER RISK; CELL ACTIVITY; CLINICAL PROTOCOL; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG WITHDRAWAL; ERADICATION THERAPY; ESOPHAGUS CANCER; GASTRIN CELL; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFECTION CONTROL; PRIORITY JOURNAL; RECURRENT DISEASE; REFLUX ESOPHAGITIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; STOMACH ACID; STOMACH ACID SECRETION; STOMACH CANCER; STOMACH PARIETAL CELL; TREATMENT INDICATION;

ESOPHAGEAL NEOPLASMS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HUMANS; STOMACH NEOPLASMS;

HELICOBACTER; HELICOBACTER PYLORI;

EID: 0041335357     PISSN: 10834389     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-5378.2003.00155.x     Document Type: Review

References (77)

1. Nakajima S, Graham DY, Hattori T, Bamba T. Strategy for treatment of Helicobacter pylori infection in adults. I. Updated indications for test and eradication therapy suggested in 2000. Curr Pharm Des 2000;6:1503-14.
2. Nakajima S, Graham DY, Hattori T, Bamba T. Strategy for treatment of Helicobacter pylori infection in adults. II. Practical policy in 2000. Curr Pharm Des 2000;6:1515-29.
3. Labenz J, Blum AL, Bayerdörffer E, Meining A, Stolte M, Börsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997;112:1442-7.
4. Cameron AJ. Epidemiology of columnar-lined esophagus and adenocarcinoma. Gastroenterol Clin North Am 1997;26:487-94.
5. Malfertheiner P, Mégraud F, O'Morain C, et al. (EHPSG). Current concepts in the management of Helicobacter pylori infection-The Maastricht 2-2000. Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
6. Correa P. Human gastric carcinogenesis. A multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;15:6735-40.
7. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
8. De Moraes-Filho JPP, Zaterka S, Pinotti HW, Bettarello A. Esophagitis and duodenal ulcer. Digestion 1974;11:338-46.
9. Boyd EJS. The prevalence of esophagitis in patients with duodenal ulcer or ulcer-like dyspepsia. Am J Gastroenterol 1996;91:1539-43.
10. Schütze K, Hentschel E, Dragosics B, Hirschl AM. Helicobacter pylori reinfection with identical organisms: transmission by the patients' spouses. Gut 1995;36:831-3.
11. Fallone CA, Barkun AN, Friedman G, et al. Is Helicobacter pylori eradication associated with gastroesophageal reflux disease? Am J Gastroenterol 2000;95:914-20.
12. Murai T, Miwa H, Ohkura R, et al. The incidence of reflux oesophagitis after cure of Helicobacter pylori in a Japanese population. Aliment Pharmacol Ther 2000;14:161-5.
13. Hamada H, Haruma K, Mihara M, et al. High incidence of reflux esophagitis after eradication therapy for Helicobacter pylori: impacts of hiatus hernia and corpus gastritis. Aliment Pharmacol Ther 2000;14:729-35.
14. Befrits R, Sjöstedt S, Ödman B. Sörngård, Lindberg G. Curing Helicobacter pylori infection in patients with duodenal ulcer does not provoke gastroesophageal reflux disease. Helicobacter 2000;5:202-5.
15. Yachida S, Saito D, Kozu T, et al. Endoscopically demonstrable esophageal changes after Helicobacter pylori eradication in patients with gastric disease. J Gastroenterol Hepatol 2001;16:1346-52.
16. Manes G, Mosca S, De Nucci C, Lombardi G, Lioniello M, Balzano A. High prevalence of reflux symptoms in duodenal ulcer patients who develop gastro-oesophageal reflux disease after curing Helicobacter pylori infection. Dig Liver Dis 2001;33:665-70.
17. Kim N, Lim SH, Lee KH. No protective role of Helicobacter pylori in the pathogenesis of reflux esophagitis in patients with duodenal or benign gastric ulcer in Korea. Dig Dis Sci 2001;46:272-432.
18. O'Connor HJ, McGee C, Ghabash NM, Cunnane K. Prevalence of esophagitis in H. pylori-positive peptic ulcer disease and the impact of eradication therapy. Hepatogastroenterology 2001;48:1064-8.
19. Koike T, Ohara S, Sekine H, et al. Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. Gut 2001;49:330-4.
20. Laheij RJ, Van Rossum LG, De Boer WA, Jansen JB. Corpus gastritis in patients with endoscopic diagnosis of reflux oesophagitis and Barrett's oesophagus. Aliment Pharmacol Ther 2002;16:887-91.
21. Calam J. The somatostatin-gastrin link of Helicobacter pylori infection. Ann Med 1995;27:569-73.
22. Ohkusa T, Fujiki K, Takashimizu I, et al. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med 2001;134:380-6.
23. Hirota WK, Loughney TM, Lazas DJ, Maydonovitch CL, Rholl V, Wong RKH. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology 1999;116:277-85.
24. Vakil N, Hahn B, McSorley D. Recurrent symptoms and gastro-oesophageal reflux disease in patients with duodenal ulcer treated for Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:45-51.
25. McColl KE, Dickson A, El-Nujumi A, El-Omar E, Kelman A. Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease. Am J Gastroenterol 2000;95:101-5.
26. Rokkas T, Ladas SD, Liatsos C, Panagou E, Karameris A, Raptis SA. Effectiveness of acid suppression in preventing gastroesophageal reflux disease (GERD) after successful treatment of Helicobacter pylori infection. Dig Dis Sci 2001;46:1567-72.
27. Malfertheiner P, Dent J, Zeijlon L, et al. Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease - results from a randomized trial programme. Aliment Pharmacol Ther 2002;16:1431-42.
28. Laine L, Dhir V. Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial. Aliment Pharmacol Ther 2002;16:1143-8.
29. Schwizer W, Thumshirn M, Dent J, et al. Helicobacter pylori and symptomatic relapse of gastrooesophageal reflux disease: a randomized controlled trial. Lancet 2001;357:1738-42.
30. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001;121:1120-6.
31. Miwa H, Sugiyama Y, Ohkusa T, et al. Improvement of reflux symptoms 3 years after cure of Helicobacter pylori infection: a case-controlled study in the Japanese population. Helicobacter 2002;7:219-24.
32. Wu JC, Chan FK, Wong SK, Lee YT, Leung WK, Sung JJ. Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis. Aliment Pharmacol Ther 2002;16:545-52.
33. Tefera S, Hatlebakk JG, Berstad AE, Berstad A. Eradication of Helicobacter pylori does not increase acid reflux in patients with mild to moderate reflux oesophagitis. Scand J Gastroenterol 2002;37:877-83.
34. Richter J. Do we know the cause of reflux disease? Eur J Gastroenterol Hepatol Supplement 1999;1:S3-9.
35. Ho KY, Kang JY. Reflux esophagitis patients in Singapore have motor and acid exposure abnormalities similar to patients in the Western hemisphere. Am J Gastroenterol 1999;94:1186-91.
36. Gutierrez O, Melo M, Segura AM, Angel A, Genta RM, Graham DY. Cure of Helicobacter pylori infection improves gastric acid secretion in patients with corpus gastritis. Scand J Gastroenterol 1997;32:664-8.
37. El-Omar EM, Oien K, El-Nujumi A, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997;113:15-24.
38. Feldman M, Cryer B, Sammer D, Lee E, Spechler SJ. Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid reflux. Am J Physiol 1999;277:G1159-64.
39. Furuta T, Baba S, Takashima M, et al. Effect of Helicobacter pylori infection on gastric juice pH. Scand J Gastroenterol 1998;33:357-63.
40. Savarino V, Mela GS, Zentilin P, et al. Effect of Helicobacter pylori eradication on 24-hour gastric pH and duodenal gastric metaplasia. Dig Dis Sci 2000;45:1315-21.
41. Iijima K, Ohara S, Sekine H, et al. Changes in gastric acid secretion assayed by endoscopic gastrin test before and after Helicobacter pylori infection. Gut 2000;46:20-6.
42. Annibale B, Aprile MR, D'ambra G, Caruana P, Bordi C, Delle Fave G. Cure of Helicobacter pylori infection in atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its related effects on body ECL-cell hyperplasia. Aliment Pharmacol Ther 2000;14:625-34.
43. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999;117:11-6.
44. Van Herwaarden MA, Samsom M, Smout AJ. 24-h recording of intragastric pH: technical aspects and clinical relevance. Scand J Gastroenterol Suppl 1999;230:9-16.
45. Bercík P, Verdú EF, Armstrong D, et al. The effect of ammonia on omeprazole-induced reduction of gastric acidity in subjects with Helicobacter pylori infection. Am J Gastroenterol 2000;95:947-55.
46. El-Omar EM, Penman ID, Ardill JE, Chittajallu RS, Howie C, McColl KE. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1996;109:681-91.
47. Moss SF, Calam J. Acid secretion and sensitivity to gastrin in patients with duodenal ulcer. effect of eradication of Helicobacter pylori. Gut 1993;34:888-92.
48. Harris AW, Gummett PA, Misiewicz JJ, Baron JH. Eradication of Helicobacter pylori in patients with duodenal ulcer lowers basal and peak acid outputs to gastrin releasing peptide and pentagastrin. Gut 1996;38:663-7.
49. Moss SF, Legon S, Bishop AE, Polak JM, Calam J. Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet 1992;17:930-2.
50. Calam J, Gibbons A, Healey ZV, Bliss P, Arebi N. How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology. Gastroenterology 1997;113:S43-9.
51. Satoh K, Kimura K, Takimoto T, Kihira K. A follow-up study of atrophic gastritis and intestinal metaplasia after eradication of Helicobacter pylori. Helicobacter 1998;3:236-40.
52. Tucci A, Poli L, Tosetti C, et al. Reversal of fundic atrophy after eradication of Helicobacter pylori. Am J Gastroenterol 1998;93:1425-31.
53. Kokkola A, Sipponen P, Rautelin H, et al. The effect of Helicobacter pylori eradication on the natural course of atrophic gastritis with dysplasia. Aliment Pharmacol Ther 2002;16:515-20.
54. Ito M, Haruma K, Kamada T, et al. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther 2002;16:1449-56.
55. Besisik F, Surucu F, Mungan Z, et al. Helicobacter pylori eradication lowers esophageal sphincter pressures in functional dyspepsia patients. Hepatogastroenterology 2001;48:1772-5.
56. Shirota T, Kusano M, Kawamura O, Horikoshi T, Mori M, Sekiguchi T. Helicobacter pylori infection correlates with severity of reflux esophagitis: with manometry findings. J Gastroenterol 1999;34:553-9.
57. Zerbib F, Bicheler V, Leray V, Joubert M, Bruley des Varannes S, Galmiche JP. H. pylori and transient lower esophageal sphincter relaxations induced by gastric distension in healthy humans. Am J Physiol Gastrointest Liver Physiol 2001;281:G350-6.
58. Manes G, Esposito P, Lioniello M, Bove A, Mosca S, Balzano A. Manometric and pH-metric features in gastro-oesophageal reflux disease patients with and without Helicobacter pylori infection. Dig Liver Dis 2000;32:372-7.
59. Rachmilewitz D, Karmeli F, Eliakim R, et al. Enhanced gastric nitric oxide synthase activity in duodenal ulcer patients. Gut 1994;35:1394-7.
60. Hirsch DP, holloway RH, Tytgat GN, Boeckxstaens GE. Involvement of nitric oxide in human transient lower esophageal sphincter relaxations and esophageal primary peristalsis. Gastroenterology 1998;115:1374-80.
61. Straathof JW, Tieleman S, Lamers CB, Masclee AA. Effect of somatostatin on lower esophageal sphincter characteristics in man. Scang J Gastroenterol 2000;35:910-5.
62. Richter JE, Pandol SJ, Castell DO, McCarthy DM. Gastroesophageal reflux disease in the Zollinger-Ellison syndrome. Ann Intern Med 1981;95:37-43.
63. Snyder N, Hughes W. Basal and calcium-stimulated gastroesophageal sphincter pressure in patients with Zollinger-Ellison syndrome. Gastroenterology 1977;72:1240-3.
64. Strader DB, Benjamin SB, Orbuch M, et al. Esophageal function and occurrence of Barrett's esophagus in Zollinger-Ellison syndrome. Digestion 1995;56:347-56.
65. Corazziari E, Pozzessere C, Dani S, Anzini F, Torsoli A. Lower esophageal sphincter response to intravenous infusions of pentagastrin in normal subjects, antrectomised and achalasic patients. Gut 1978;19:1121-4.
66. Henderson JM, Lidgard G, Osborne DH, Carter DC, Heading RC. Lower oesophageal sphincter response to gastrin - pharmacological or physiological? Gut 1978;19:99-102.
67. Walker CO, Frank SA, Manton J, Fordtran JS. Effect of continuous infusion of pentagastrin on lower esophageal sphincter pressure and gastric acid secretion in normal subjects. J Clin Invest 1975;56:218-25.
68. Heil T, Mattes P, Raptis S. Effects of somatostatin and human gastrin I on the lower esophageal sphincter in man. Digestion 1977;15:461-8.
69. Jennewein HM, Hummelt H, Siewert R, Waldeck F. The effect of intravenous infusion of synthetic human gastrin-I on lower esophageal sphincter (LES) pressure in the dog and its relation to gastrin level. Digestion 1976;14:376-80.
70. Allescher HD, Stoschus B, Wunsch E, Schusdziarra V, Classen M. Effect of human gastrin-17 with and without acid suppression on human esophageal motility. Z Gastroenterol 1995;33:385-91.
71. Straathof JW, Lamers CB, Masclee AA. Effect of gastrin-17 on lower esophageal sphincter characteristics in man. Dig Dis Sci 1997;42:2547-51.
72. Csendes A, Oster M, Brandsborg O, Moller J, Brandsborg M, Amdrup E. Gastroesophageal sphincter pressure and serum gastrin reaction to food stimulation in normal subjects and in patients with gastric or duodenal ulcer. Scand J Gastroenterol 1978;13:363-8.
73. Stanghellini V. Three-month prevalence rates of gastrointestinal symptoms and the influence of demographic factors: results from the Domestic International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol 1999;34:20-8.
74. Tefera S, Hatlebakk JG, Berstad A. The effect of Helicobacter pylori eradication on gastro-oesophageal reflux. Aliment Pharmacol Ther 1999;13:915-20.
75. Anand BS, Graham DY. Ulcer and gastritis. Endoscopy 1999;31:215-25.
76. Nakajima S, Hattori T, Bamba T. Mechanisms of reflux esophagitis after cure of Helicobacter pylori infection and the risk of esophageal adenocarcinoma compared with the risk of gastric cancer. Jap J Helicobacter Res 2001;3:4-11.
77. Uemura N, Mukai T, Okamoto S, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997;6:639-42.